MX2022016236A - Metodos de tratamiento del trastorno del espectro de la neuromielitis optica. - Google Patents

Metodos de tratamiento del trastorno del espectro de la neuromielitis optica.

Info

Publication number
MX2022016236A
MX2022016236A MX2022016236A MX2022016236A MX2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A
Authority
MX
Mexico
Prior art keywords
methods
spectrum disorder
neuromyelitis optica
optica spectrum
treating
Prior art date
Application number
MX2022016236A
Other languages
English (en)
Spanish (es)
Inventor
William Rees
Michael Smith
Eliezer Katz
Nanette Mittereder
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of MX2022016236A publication Critical patent/MX2022016236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2022016236A 2020-06-30 2021-06-30 Metodos de tratamiento del trastorno del espectro de la neuromielitis optica. MX2022016236A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063046133P 2020-06-30 2020-06-30
US202063052093P 2020-07-15 2020-07-15
US202063071092P 2020-08-27 2020-08-27
PCT/US2021/039911 WO2022006283A2 (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Publications (1)

Publication Number Publication Date
MX2022016236A true MX2022016236A (es) 2023-03-29

Family

ID=79321915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016236A MX2022016236A (es) 2020-06-30 2021-06-30 Metodos de tratamiento del trastorno del espectro de la neuromielitis optica.

Country Status (11)

Country Link
US (1) US20230406928A1 (https=)
EP (1) EP4172211A4 (https=)
JP (1) JP2023534916A (https=)
KR (1) KR20230030642A (https=)
CN (1) CN116234571A (https=)
AU (1) AU2021299307A1 (https=)
BR (1) BR112022026747A2 (https=)
CA (1) CA3178954A1 (https=)
IL (1) IL299381A (https=)
MX (1) MX2022016236A (https=)
WO (1) WO2022006283A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021368769A1 (en) * 2020-10-29 2023-06-08 Viela Bio, Inc. Use of an anti-cd19 antibody to treat autoimmune disease
CN117797245A (zh) * 2023-12-29 2024-04-02 广州赛莱拉干细胞科技股份有限公司 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020263418A1 (en) * 2019-04-24 2021-11-11 Viela Bio, Inc. Use of an anti-CD19 antibody to treat autoimmune disease
AU2021368769A1 (en) * 2020-10-29 2023-06-08 Viela Bio, Inc. Use of an anti-cd19 antibody to treat autoimmune disease

Also Published As

Publication number Publication date
US20230406928A1 (en) 2023-12-21
CN116234571A (zh) 2023-06-06
EP4172211A4 (en) 2024-07-10
BR112022026747A2 (pt) 2023-01-24
JP2023534916A (ja) 2023-08-15
EP4172211A2 (en) 2023-05-03
WO2022006283A3 (en) 2022-02-03
AU2021299307A1 (en) 2022-12-22
KR20230030642A (ko) 2023-03-06
CA3178954A1 (en) 2022-01-06
WO2022006283A2 (en) 2022-01-06
IL299381A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2022016236A (es) Metodos de tratamiento del trastorno del espectro de la neuromielitis optica.
EP3878862A3 (en) Anti-coronavirus antibodies and methods of use
MX2022016061A (es) Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos.
MX2022002682A (es) Anticuerpos anti-cd73.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BRPI0515884A (pt) métodos de diagnóstico e tratamento de complicações da gravidez
WO2020209988A3 (en) Diverse marker panel for ptsd diagnosis and treatment
WO2020185541A3 (en) Zilucoplan as deep tissue penetrating c5 inhibitor
BR112021024634A2 (pt) Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno
WO2021188881A3 (en) Compositions and methods for detecting and treating sars-cov-2
MX2022011050A (es) Anticuerpos anti-cd36 y su uso para tratar cancer.
EA202193111A1 (ru) Композиции и способы для лечения рака
WO2021257816A3 (en) Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury
WO2019241730A8 (en) Increasing immune activity through modulation of postcellular signaling factors
WO2021195470A3 (en) Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2
EA202092487A1 (ru) Ферменты кинурениназы человека и их применение
MX2025004473A (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
BR112013019674A2 (pt) método para remoção de metoxipirazinas de vinho e/ou suco, para a remoção de compostos indesejáveis no vinho e/ou suco, para a modificação do perfil organoléptico de vinho e/ou suco e para a remoção de um composto-alvo de vinho e/ou suco
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX2025008198A (es) Terapia con moléculas de proteínas de unión a lípidos
MX2022007116A (es) Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis optica.
BR112023000422A2 (pt) Métodos para identificar anticorpos de reação cruzada com coronavírus
WO2019066620A3 (ko) 항 c-met 항체 및 이의 용도
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도
MX2022015772A (es) Proteínas enpp1 o enpp3 solubles y sus usos.